A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
A new study shows that an ancient mechanism of regulating a cell’s protein repertoire allows malaria parasites to hide from fast-acting artemisinin drugs and survive.
The way SARS-CoV-2 mutates in immunocompromised patients to escape Paxlovid could help chemists design better drugs that are more difficult for the virus to sidestep.
Columbia researchers have found why babies are susceptible to repeated bouts of common respiratory infections—but also have a unique weapon to fight off new pathogens that healthy adults lack.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.
At the award ceremony, the nation's top infectious disease expert spoke about his decades-long effort to end the HIV/AIDS crisis (see video in the article).
Columbia’s cell therapy lab, which creates customized cell therapies, is testing its first product, T cells trained to fight dangerous infections in transplant patients.
Obstacles remain before the world reaches the point of eliminating AIDS, but new prevention technologies and outreach programs are reasons to be optimistic about the future.
The diminished power of the immune system in older adults is usually blamed on the aging process. A new study shows that decades of inhaled particulates due to air pollution also take a toll.